Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Safety and Duration in Advanced NSCLC
NCT02066636Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5) up to 88 months. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02066636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066636.